Ferric Citrate for the Transition From CKD Stage 4/5 to CKD Stage 5D

Completed · Phase 3

Conditions studied: Chronic Kidney Disease, Hyperphosphatemia, Iron Deficiency Anemia, Renal Insufficiency

In brief

It is the investigators hypothesis that participants treated with Ferric Citrate (FC) during the non-dialysis CKD stage (4/5) with sufficient duration prior to initiating RRT, will result in improved biochemical control of anemia (Hb, TSAT) and mineral metabolism (P, FGF23) and furthermore, will result in a reduced need for ESA and intravenous iron. The investigators further hypothesize that effective treatment of anemia and mineral metabolism with FC in the pre-dialysis and transition period will result in improved physical functioning, reduced hospitalization and reduced total cost of care when compared to participants receiving contemporaneously provided standard of care therapy.

Key facts

Study ID

NCT02492620

Run by

Denver Nephrologists, P.C.

People needed

200

Starts

2015-03-01

Expected to finish

2017-11-01

Last updated by the study team

2018-08-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age >18 years at screening visit
• Serum phosphate > or equal to 3.0 mg/dL obtained at screening
• CKD with eGFR < or equal to 20 mL/min obtained at screening*
• Hemoglobin (Hgb) >8.0 g/dL obtained at screening
• TSAT <55% obtained at screening
• Females of child bearing potential with negative serum pregnancy test obtained at screening
• Willing and able to give written informed consent
• Anticipated to have > or equal to 8 weeks prior to need for initiating RRT in the opinion of the investigator

You may not qualify if…

• Liver enzymes (ALT/AST) >X3 times upper limit of normal at screening
• Use of IV iron, blood transfusions or ESA agents within 2 weeks prior to the screening visit and prior to the Day 1 visit.
• Evidence of acute kidney injury (i.e., no CKD) or planned need for RRT within 12 weeks of screening
• Scheduled kidney transplant within 24 weeks of screening
• Contra-indication to ferric citrate: iron overload syndrome, allergic reaction or known intolerance to ferric citrate
• Clinically significant medical condition felt to interfere with tolerance of oral medication
• Life expectancy < 6 months or confirmed conviction that subject does NOT want to initiate RRT despite a decline in kidney function
• Active drug or alcohol dependence or abuse (excluding tobacco use or marijuana use) within the 12 months prior to screening (in the opinion of the PI)
• Psychiatric disorder that interferes with the subject's ability to comply with the study protocol in the opinion of the PI
• Any other medical condition that, in the opinion of the PI, renders the subject unable to or unlikely to complete the trial or that would interfere with optimal participation in the trial or produce significant risk to the subject
• Inability to cooperate with study personnel or study procedures
• Females who are pregnant or breastfeeding
• Receiving or has received any investigational drug with in the past 30 days prior to the Day 1 visit

Where it is running

• Denver Nephrologists, P.C. — Denver, Colorado, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.